Abstract
Background Despite the large toll of opioid use disorder (OUD), genome-wide association studies (GWAS) of OUD to date have yielded few susceptibility loci.
Methods We performed a large-scale GWAS of OUD in individuals of European (EUR) and African (AFR) ancestry, optimizing genetic informativeness by performing MTAG (Multi-trait analysis of GWAS) with genetically correlated substance use disorders (SUDs). Meta-analysis included seven cohorts: the Million Veteran Program (MVP), Psychiatric Genomics Consortium (PGC), iPSYCH, FinnGen, Partners Biobank, BioVU, and Yale-Penn 3, resulting in a total N=639,709 (Ncases=20,858) across ancestries. OUD cases were defined as having lifetime OUD diagnosis, and controls as anyone not known to meet OUD criteria. We estimated SNP-heritability (h2SNP) and genetic correlations (rg). Based on genetic correlation, we performed MTAG on OUD, alcohol use disorder (AUD), and cannabis use disorder (CanUD).
Results The EUR meta-analysis identified three genome-wide significant (GWS; p≤5×10−8) lead SNPs—one at FURIN (rs11372849; p=9.54×10−10) and two OPRM1 variants (rs1799971, p=4.92×10−09 ; rs79704991, p=1.37×10−08; r2=0.02). Rs1799971 (p=4.91×10−08) and another OPRM1 variant (rs9478500; p=1.95×10−8; r2=0.03) were identified in the cross-ancestry meta-analysis. Estimated h2 SNP was 12.75%, with strong rg with CanUD (rg =0.82; p=1.14×10−47) and AUD (rg=0.77; p=6.36×10−78). The OUD-MTAG resulted in 18 GWS loci, some of which map to genes or gene regions that have previously been associated with psychiatric or addiction phenotypes.
Conclusions We identified multiple OUD variant associations at OPRM1, single variant associations with FURIN, and 18 GWS associations in the OUD-MTAG. OUD is likely influenced by both OUD-specific loci and loci shared across SUDs.
Competing Interest Statement
HRK is a member of scientific advisory boards for DIcerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sophrosyne Pharmaceuticals; and a member of the American Society of Clinical Psychopharmacologys Alcohol Clinical Trials Initiative, which during the past three years was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018.
Funding Statement
Funding: This work was supported by NIH grants R01DA054869 (JG, HE, AA), R01 AA026364 (JG), T32 AA028259 (JDD), K01 AA028292 (RLK), U24 AA020794 (ACJ), U01 AA020790 (ACJ), U24 AA022001(ACJ), U10 AA013566 (ACJ), K02 DA032573 (AA), DP1 DA054394 (SSR), R33 DA047527 (RP), and F32 MH122058 (FRW); the Brain & Behavior Research Foundation (HZ); the California Tobacco-Related Disease Research Program (T29KT0526; SSR); The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), U01 MH109514-01 (ADB) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB); and by funding from the Department of Veterans Affairs Office of Research and Development, USVA, grants I01CX001849, I01BX003342, I01BX004820, and I01 CX001734, and the VA Cooperative Studies Program study, no. 575B. This publication does not represent the views of the Department of Veterans Affairs or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Other than Yale-Penn, this study involved de-identified data. The work was approved as appropriate by the Central VA institutional review board (IRB) and site-specific IRBs, including Yale University School of Medicine and VA CT, and was conducted in accordance with all relevant ethical regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by NIH grants R01DA054869 (JG, HE, AA), R01 AA026364 (JG), T32 AA028259 (JDD), K01 AA028292 (RLK), U24 AA020794 (ACJ), U01 AA020790 (ACJ), U24 AA022001(ACJ), U10 AA013566 (ACJ), K02 DA032573 (AA), DP1 DA054394 (SSR), R33 DA047527 (RP), and F32 MH122058 (FRW); the Brain & Behavior Research Foundation (HZ); the California Tobacco-Related Disease Research Program (T29KT0526; SSR); The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), U01 MH109514-01 (ADB) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB); and by funding from the Department of Veterans Affairs Office of Research and Development, USVA, grants I01CX001849, I01BX003342, I01BX004820, and I01 CX001734, and the VA Cooperative Studies Program study, no. 575B. This publication does not represent the views of the Department of Veterans Affairs or the United States Government.
Disclosures: HRK is a member of scientific advisory boards for DIcerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sophrosyne Pharmaceuticals; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which during the past three years was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018.
Data Availability
All data produced in the present study will be available upon request to the authors
